Odyssey Therapeutics, Inc. filed a Form S-1 registration statement for an initial public offering on 2025-01-17. It has amended it 1 time. It filed its final prospectus on 2026-05-08, at a public offering price of $18.00 per share. Each fact below is quoted from the filing named with it.
What the filings say
Listing
Our common stock has been approved for listing on the Nasdaq Capital Market, or Nasdaq, under the trading symbol “ODTX.”From the 424B4 filed 2026-05-08
Shares offered
This is an initial public offering of shares of common stock of Odyssey Therapeutics, Inc. We are offering 15,500,000 shares of our common stock.From the 424B4 filed 2026-05-08
Offering price
The initial public offering price is $18.00 per share.From the 424B4 filed 2026-05-08
Use of proceeds
We intend to use the net proceeds to us from this offering to (i) advance the clinical development of OD-001, our most advanced product candidate, through 12-week induction readouts from our planned phase 2a combination trial and phase 2b monotherapy trial in ulcerative colitis, (ii) advance our SLC15A4 program through IND-enabling activities and our planned phase 1/2a clinical trial and (iii) fund additional discovery, preclinical and clinical activities for disclosed or future programs, enabling capabilities and for general corporate purposes, working capital and other capital expenditures.From the S-1 filed 2026-04-17
Net loss or income
For the years ended December 31, 2025 and 2024, we reported a net loss of $148.6 million and $129.3 million, respectively.From the S-1/A filed 2026-05-04
Withdrawal
Odyssey Therapeutics, Inc. (the Company ) hereby requests, pursuant to Rule 477 under the Securities Act of 1933, as amended (the Securities Act ), that the U.S. Securities and Exchange Commission (the SEC ) consent to the withdrawal of the Companys Registration Statement on Form S-1 (File No. 333-284332), initially filed with the SEC on January 17, 2025, together with all exhibits and amendments thereto (collectively, the Registration Statement ), as of the date hereof or at the earliest practicable date hereafter.From the RW filed 2025-06-09
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2025-01-17 | Registration statement filed | S-1 |
| 2025-06-09 | Request to withdraw a registration (Form S-1) | RW |
| 2026-04-17 | Registration statement filed | S-1 |
| 2026-05-04 | Registration statement amended | S-1/A |
| 2026-05-08 | Final prospectus filed: the offering is priced | 424B4 |
Tools for this story
Each opens in a new tab, filled in for Odyssey Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.